Loading stock…

Hims & Hers Health, Inc. (HIMS) Stock Verdict & Ratings | Investment Bastion

Stock Verdict·Updated 1d ago

Hims & Hers Health, Inc.

HIMSMarket cap $6.88BPrice $29.5

Country🇺🇸United States

SectorHealthcare

IndustryHealthcare Services

Sells prescription meds, skincare, and mental health treatments directly to consumers through telehealth, skipping the doctor's office entirely. Built a multi-billion-dollar business on subscriptions for hair loss, ED, and weight loss drugs that people used to whisper about.

In Bastion Portfolios?

52W Return-41%Global Market +16%?

01Key Ratings

How does this stock score across Bastion factors?

Growth

Historical Revenue

Rev CAGR (3y)+65%10

Revenue Forecast

Rev CAGR (1y)+37%9

Rev CAGR (3y)+24%9

Rev CAGR (5y)+14%9

Earnings Forecast

EPS Growth Y+1+23%8

EPS Growth Y+2+26%8

EPS Growth Y+3+64%10

Quality

Margins

EBIT Margin-4%1

Net Income Margin-6%1

Free Cash Flow Margin3%3

Debt

Net Debt/EBITDAna–

Efficiency

ROE-32%1

ROA-5%1

Earnings Stability44

GEAR+WEAK19

Overall rating across all five factors

Value

Price Multiples

P/E Ratio (Forward)273

P/E Ratio (Forward 3y)203

P/BV21.21

EV Multiples

EV/EBITDA Fwd252

EV/EBIT Fwdna–

Yield

Free Cash Flow Yield1.2%3

Dividend Yieldna–

Momentum

Short term

1 month return+6%9

3 month return-19%2

YTD return-9%3

Mid term

Price vs 52wHigh45%1

1 year return-49%1

Long term

3 year return+363%10

5 year return+296%9

Risk Shield

Price Risk

Beta2.51

Volatility89%1

Free Cash Flow

Free Cash Flow Margin3%3

Free Cash Flow Yield1.2%3

Quality

ROCE-5%1

Earnings Stability44

Net Debt/EBITDAna–

02Growth

Is it actually growing, and how fast?

HIMSHims & Hers Health

Revenue FY25$2.3B

GROWTH RATING↗

VERY STRONG94 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+65%10

Revenue, next 1Y+37%9

Revenue, next 3Y, CAGR+24%9

Revenue, next 5Y, CAGR+14%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+23%8

EPS growth, FY27E+26%8

EPS growth, FY28E+64%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 94% of companies worldwide.

Revenue grew 65%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 24%/yr over the next 3 years, ahead of most of the market.9/10

The runway holds up: revenue is set to grow 14%/yr over five years.9/10

WATCH

Revenue grew 65%/yr over the last 3 years; forecasts see it cooling to 24%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE39 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+6%9

3-month return-19%2

YTD return-9%3

MID & LONG-TERM▾SCORE

% of 52-week high45%1

1-year return-49%1

3-year return+363%10

5-year return+296%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +363% over three years and +296% over five, ahead of 90% of the market.

Strong recent results. The stock is outperforming over the past month (+6%).

WATCH

None flagged.

WEAKNESSES

It's down 49% over the past year, now 55% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-19%) and so far this year (-9%).

BOTTOM LINE

Outperformer in a Drawdown

A proven multi-year compounder now in a meaningful pullback well below its 52-week high. This is the classic fork: either a buy-the-dip in an intact uptrend, or the early stage of a trend change. Wait for the short-term slide to stabilise before adding. The one thing to watch: the one-year trend is weak.

04Value

Are you paying a fair price for it?

Stop guessing on Hims & Hers. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community

Loading charts…

02Growth

Is it actually growing, and how fast?

HIMSHims & Hers Health

Revenue FY25$2.3B

GROWTH RATING↗

VERY STRONG94 / 100

REVENUE GROWTH▾SCORE

Revenue, last 3Y, CAGR+65%10

Revenue, next 1Y+37%9

Revenue, next 3Y, CAGR+24%9

Revenue, next 5Y, CAGR+14%9

EARNINGS FORECAST▾SCORE

EPS growth, FY26E+23%8

EPS growth, FY27E+26%8

EPS growth, FY28E+64%10

GROWTH ASSESSMENT

STRENGTHS

It out-grows 94% of companies worldwide.

Revenue grew 65%/yr over the last 3 years, ahead of 90% of companies worldwide.10/10

Revenue is set to grow 24%/yr over the next 3 years, ahead of most of the market.9/10

The runway holds up: revenue is set to grow 14%/yr over five years.9/10

WATCH

Revenue grew 65%/yr over the last 3 years; forecasts see it cooling to 24%/yr.

WEAKNESSES

The company is loss-making, so its revenue growth is not backed by profit yet.

BOTTOM LINE

Top-Line Rocket

A top-tier grower that is slowing. The one thing to watch: the company is not profitable yet.

03Price Momentum

Is the market behind it right now?

MOMENTUM RATING↗

AVERAGE39 / 100

SHORT-TERM RETURNS▾SCORE

1-month return+6%9

3-month return-19%2

YTD return-9%3

MID & LONG-TERM▾SCORE

% of 52-week high45%1

1-year return-49%1

3-year return+363%10

5-year return+296%9

MOMENTUM ASSESSMENT

STRENGTHS

Magnificent long-term results. Long-term holders have seen +363% over three years and +296% over five, ahead of 90% of the market.

Strong recent results. The stock is outperforming over the past month (+6%).

WATCH

None flagged.

WEAKNESSES

It's down 49% over the past year, now 55% below its 52-week high. That is lagging the market.

The stock is underperforming over three months (-19%) and so far this year (-9%).

BOTTOM LINE

Outperformer in a Drawdown

04Value

Are you paying a fair price for it?

Stop guessing on Hims & Hers. Get the full investment case.

Premium

$20.75/month

Billed annually at $249/year $348

✓
Stock VerdictValuation and investment strategy for 4,000+ stocks. Days of hedge fund analyst research, done in 2 minutes.
✓
RadarFind your next investment idea: top-ranked stocks across all 9 Bastion strategies.
✓
Portfolio ManagerCheck if Bastion algorithms added the stock you care about to their portfolios.

Secure via Stripe

Trusted by 1,000+ investors in our community